In vitro activity of BRL 17421 against Haemophilus influenzae, Neisseria gonorrhoeae, and Branhamella catarrhalis
Open Access
- 1 January 1982
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 21 (1) , 166-167
- https://doi.org/10.1128/aac.21.1.166
Abstract
BRL 17421, a novel beta-lactam antibiotic, was tested in vitro against fastidious gram-negative bacteria and compared with amoxicillin and amoxicillin plus clavulanic acid. The compound showed good activity against Haemophilus influenzae (range of minimal inhibitory concentrations, 0.2 to 1 microgram/ml), Neisseria gonorrhoeae (0.007 to 0.5 microgram/ml), and Branhamella catarrhalis (0.03 to 0.1 microgram/ml). BRL 17421 exhibited excellent stability against the TEM-type beta-lactamase of H. influenzae and N. gonorrhoeae, and its activity was little affected by inoculum size. Minimal lethal concentrations of BRL 17421 for 10(7) colony-forming units of H. influenzae ranged between 0.5 and 4 micrograms/ml.This publication has 4 references indexed in Scilit:
- BRL 17421, a novel beta-lactam antibiotic, highly resistant to beta-lactamases, giving high and prolonged serum levels in humansAntimicrobial Agents and Chemotherapy, 1981
- In vitro and in vivo synergism between amoxicillin and clavulanic acid against ampicillin-resistant Haemophilus influenzae type bAntimicrobial Agents and Chemotherapy, 1981
- Antibiotic Susceptibility of Neisseria gonorrhoeae Strains from Europe and AfricaAntimicrobial Agents and Chemotherapy, 1979
- Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitisThe Journal of Pediatrics, 1976